Navigation Links
Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
Date:5/4/2008

requiring outpatient medical management within this population.

The overall incidence and severity of adverse events (AEs) were similar between the motavizumab and the placebo groups in these Native American infants. The mortality rates were not statistically different between groups (0.4 percent in the placebo arm, n=2 and 0.3 percent in the motavizumab arm, n=3) and were not considered to be related to the study drug. As was suggested in the pivotal Phase 3 trial conducted in high-risk, preterm infants, rates of skin reactions were more common following Motavizumab than placebo (by an approximately 2 percent increase in frequency). Motavizumab was otherwise well tolerated.

About RSV

Each year, up to 125,000 infants in the U.S. are hospitalized with severe RSV infections, the leading cause of lower respiratory tract infections in infants in the United States. RSV is the most common respiratory infection in infancy or childhood. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday. Children born prematurely as well as those with chronic lung disease (CLD) or congenital heart disease (CHD) are at highest risk for severe disease and hospitalization due to RSV. The virus may also cause severe illness in other high-risk groups such as the elderly, those with underlying respiratory or cardiac disease, and those with compromised immune systems (e.g., bone marrow transplant patients). Otherwise healthy infants in some Native American populations have demonstrated rates of RSV hospitalization that are similar to those among children with underlying medical conditions in the general U.S. population.

About Motavizumab

Motavizumab is an investigational humanized MAb being evaluated for its potential to prevent serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 4, 2015 Microbrush International, a leading ... in dental restorative procedures, today announced the acquisition ... an innovative sectional matrix system used in dental ... about the opportunity to add DentiSmart to our ... Frymark , VP and General Manager of Microbrush. ...
(Date:5/4/2015)... 4, 2015  The board of directors of Eli Lilly ... for the second quarter of 2015 of $0.50 per share ... payable June 10, 2015, to shareholders of record at the ... Lilly and Company Lilly is a global healthcare leader that ... around the world. We were founded more than a century ...
(Date:5/4/2015)... -- PAREXEL International Corporation (NASDAQ: PRXL ) announced today ... on Monday, May 18, 2015, in New York City.  ... will be making a presentation on PAREXEL and discussing business ... of the presentation will be available through the "Investors" section ... Events portion of the main page, and a replay of ...
Breaking Medicine Technology:Microbrush International Announces Acquisition of DentiSmart 2PAREXEL International to Present at UBS Healthcare Conference 2
... , Strategic collaboration with Ipsen for marketing rights ... and the US , Photocure to commercialise the ... ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic ... a new commercial strategy for Hexvix, its flagship product  to ...
... FRANCISCO, Calif., Sept. 26, 2011 diaDexus, Inc. (OTC ... focused on the development and commercialization of patent-protected in ... today announced the Board of Directors, appointment of a ... a new chief business officer, R. Michael Richey. Dr. ...
Cached Medicine Technology:Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 2Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 3Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 4Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 5Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 6Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 7Photocure Announces new Commercial Strategy for Hexvix(R), the Innovative Product for Improved Detection of Bladder Cancer 8diaDexus Appoints New CEO Brian E. Ward, Ph.D. and New CBO Michael Richey 2diaDexus Appoints New CEO Brian E. Ward, Ph.D. and New CBO Michael Richey 3diaDexus Appoints New CEO Brian E. Ward, Ph.D. and New CBO Michael Richey 4diaDexus Appoints New CEO Brian E. Ward, Ph.D. and New CBO Michael Richey 5
(Date:5/4/2015)... (PRWEB) May 04, 2015 The ... Gregs G. Thomopulos, P.E., Chairman of Stanley Consultants ... (ISI) board of directors for a three-year term. , ... (APWA) and the American Society of Civil Engineers (ASCE). ... sustainability rating system for civil infrastructure called Envision. Launched ...
(Date:5/4/2015)... HHT is a rare but cruel and ... can have seemingly mild symptoms like frequent nosebleeds, it ... Hemorrhagic Telangiectasia (HHT) is a hereditary disorder resulting in ... connections between an artery and a vein. These abnormalities ... may also be present in the lungs, brain and ...
(Date:5/4/2015)... May 04, 2015 The University ... today launched a new initiative at UC Davis ... generation of physicians committed to advancing Latino health. ... Medicos, or Preparing Students to Be Physicians, (“Prep ... will provide scholarships, mentorship and internship opportunities, a ...
(Date:5/4/2015)... Each year, the Susan G. Komen organization hosts 5K ... breast cancer. This year, Dr. Mark Deutsch and his staff ... sponsor for the 25th annual Susan G. Komen Greater Atlanta ... Square Mall. , The Komen organization hopes have 10,000 participants ... Perimeter Plastic Surgery has not only taken on the role ...
(Date:5/4/2015)... 2015 Johnson & Wales University (JWU) held ... science academic center on Wednesday, April 22. , Johnson & ... made available by the re-alignment of Interstate-195. JWU’s new academic ... and Chestnut streets in Providence, is scheduled to be completed ... of land the university purchased in 2012. , “It has ...
Breaking Medicine News(10 mins):Health News:Thomopulos Appointed to Institute for Sustainable Infrastructure Board 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 2Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 3Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 4Health News:New UC Davis Program Targets Next Generation of Physicians to Advance Latino Health 5Health News:Perimeter Plastic Surgery Sponsors 2015 Susan G. Komen Greater Atlanta "Race for the Cure" 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 2Health News:Johnson & Wales University “Breaks Ground” On New $40 Million Engineering and Science Academic Center 3
... . The death rate from injuries ... urban areas, according to a new study by researchers ... Center for Injury Research and Policy. Rural males of ... from injuries than urban males, and the overall rate ...
... SCOTTSDALE, Ariz., and LONDON, Ontario Jan. 12, 2010 ... Inc. (COTI) (TSXV:COT) announced today that they will work ... promising new anti-cancer drug called COTI-2. This easily ... COTI of London, Ontario, Canada. This working relationship resulted ...
... , ... from the bimonthly biomedical journal, Molecular Medicine. Molecular Medicine publishes research concerned with the ... for disease diagnosis, treatment and prevention. , ... (Vocus) January 12, 2010 -- By the time a person ...
... , , NASHVILLE, Tenn. , Jan. ... provider of healthcare revenue and payment cycle management solutions, today announced that ... Healthcare Services Conference to be held from January 25 to 27, ... Tracy Bahl , Executive Chairman, will begin at 11:45 a.m. Eastern ...
... cuts that risk significantly, study finds , TUESDAY, Jan. 12 ... increase in resting heart rate boosts the risk of dying ... has found. , Norwegian researchers tracked the health of about ... of 18 years. During that time, 6,033 men and 4,442 ...
... ... participate in SharpBrains Summit without taking a single flight , ... San Francisco, CA (PRWEB) ... fitness, today announced the inaugural SharpBrains Summit, the first global and virtual conference ...
Cached Medicine News:Health News:Significant urban-rural disparities in injury mortality seen in China 2Health News:TD2 and Critical Outcome Technologies Inc. develop novel anti-cancer drug 2Health News:TD2 and Critical Outcome Technologies Inc. develop novel anti-cancer drug 3Health News:News from the Latest Issue of Molecular Medicine 2Health News:Emdeon to Present at the Jefferies Global Healthcare Services Conference 2Health News:Faster Heart Rate May Raise Risk of Heart Attack Death 2Health News:First Global, Virtual Summit on Cognitive Health and Performance Features 200 Sharp Brains 2Health News:First Global, Virtual Summit on Cognitive Health and Performance Features 200 Sharp Brains 3Health News:First Global, Virtual Summit on Cognitive Health and Performance Features 200 Sharp Brains 4
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
500L...
... fixed pipette is ideal for ... volume. Fixed volume FInnpipettes offer ... as other Finnpipette Digital pipettes: ... blow-out (1-40ul), Soft-touch tip ejection, ...
Medicine Products: